Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-05-28 Declaration of Voting R…
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer under the Securities Exchange Act of 1934. The key content is the "Results of Annual General Meeting" held on May 22, 2025, detailing the shareholder vote on the re-election of a director. The document includes voting results and references the AGM notice and explanatory statement. The document is 4379 characters long, which is relatively short but contains detailed voting results rather than just an announcement of the AGM or a report publication. The primary focus is on the official results of the shareholder vote at the AGM, which fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). It is not a full Annual Report, nor a proxy solicitation, nor a management or board change announcement. Therefore, the correct classification is DVA with high confidence.
2025-05-28 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 by Kazia Therapeutics Limited. It reports the results of the Annual General Meeting (AGM) held on May 22, 2025, specifically the shareholder vote on the re-election of a director. The document includes voting results and references the AGM notice and explanatory statement. The content is focused on the announcement of voting results from the AGM, not the AGM materials themselves or a full annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is a direct report of voting results, not a report publication announcement or regulatory filing. Confidence is high due to clear identification of AGM voting results and the form type (6-K) used for such announcements.
2025-05-28 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, indicating it is a current report of a foreign private issuer. The content focuses on the results of the Annual General Meeting (AGM) held on May 22, 2025, specifically the shareholder vote on the re-election of a director. The document provides detailed voting results and references the AGM notice and explanatory statement. The document length is 4377 characters, which is relatively short but contains substantive information about the voting results rather than just announcing the report's availability. Therefore, it is not a mere announcement but an official declaration of voting results from the AGM. This matches the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'.
2025-05-28 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, reporting the results of the Annual General Meeting (AGM) held on May 22, 2025. The content focuses on the voting results for the re-election of a director, Robert Apple. The document does not contain detailed financial statements or comprehensive reports but rather the official announcement of voting results from the AGM. According to the filing definitions, announcements of shareholder vote results at general meetings fall under Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2215 characters), consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, the appropriate classification is DVA with high confidence.
2025-05-28 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 by Kazia Therapeutics Limited, a foreign private issuer. It includes a prospectus supplement and a business update press release dated May 15, 2025. The content primarily provides a business update, clinical trial progress, capital raising activities, and corporate developments such as a reverse stock split and Nasdaq compliance notification. It also includes insider share purchase information. The document does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a full earnings release (ER) but includes some financial and corporate updates. The document is a regulatory filing providing current business and corporate information, including a press release, and is filed as a Form 6-K, which is a common regulatory filing for foreign private issuers to report material information. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-05-15 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a prospectus supplement and a business update press release dated May 15, 2025. The content covers recent progress, clinical trial updates, capital raising, regulatory updates, and corporate actions such as a reverse ADS split and insider share purchase. The document is not a full annual or quarterly report, nor is it an earnings release or a proxy statement. It is a regulatory filing providing current business and corporate updates, including a press release incorporated by reference. The document is lengthy (15,000 characters) and contains substantive information but is primarily a current report rather than a detailed financial report or management discussion. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and reports that do not fit other specific categories.
2025-05-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.